News

Featured

Skylark Bio Doses First Patient in SONIX Phase 1/2 Trial of SKY-GJB2 for GJB2-Related Pediatric Deafness

Read Press Release

Recent News

Skylark Bio Doses First Patient in SONIX Phase 1/2 Trial of SKY-GJB2 for GJB2-Related Pediatric Deafness

August 11, 2026

Skylark Bio and Forge Biologics Announce Strategic AAV Development and cGMP Manufacturing Partnership Supporting Skylark’s Clinical Development

Skylark Bio to Present New Preclinical Data for its Pendrin Gene Therapy Program for Hearing Loss at ASGCT 2026

Media Coverage

Skylark Bio launches gene therapy trial for GJB2-related deafness

Frequence Audio

August 18, 2026

Gene therapy trial for most common genetic cause of inherited paediatric deafness

Hearing Practitioner News

August 15, 2026

Skylark trials gene therapy for common form of child deafness

August 13, 2026

Skylark Bio doses first patient in Phase 1/2 trial for GJB2-related deafness

Discover Pharma

August 13, 2026

First patient in Skylark Bio’s Phase I/II trial receives SKY-GJB2 gene therapy

Clinical Trials Arena

August 12, 2026

ASGCT 2026: Skylark Bio is developing a gene therapy for the largest cause of pediatric deafness. They have plans to be in the clinic this summer and early data will come by the end of the year